The pharmacological treatment of dyslipidemia, a major modifiable risk factor for developing
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …

Increased plasma levels of low-density lipoprotein cholesterol (LDL-C) are causally
associated with atherosclerotic cardiovascular disease (ASCVD), and statins that lower LDL …

Abstract Background The Food and Drug Administration has approved Proprotein
Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors for the treatment of dyslipidemia …

Background The impact of the stepwise implementation of the 2019 European Society of
Cardiology (ESC)/European Atherosclerosis Society (EAS) treatment algorithm on low …

Background and aims Variability in low-density lipoprotein-cholesterol (LDL-C) level control
at a population level is associated with poor cardiovascular outcomes. Limited data exist on …

Abstract Background and aims Proprotein Convertase Subtilisin/Kexin type 9 inhibitors
(PCSK9i) are recommended in patients at high and very-high cardiovascular (CV) risk, with …

Objectives Dyslipidemia is a prevalent condition with significant morbidity and mortality
across the world, including in the Arabian Gulf. The present study aimed to describe the …

Introduction A high proportion of Canadian patients with acute myocardial infarction (AMI) do
not achieve the threshold low-density lipoprotein cholesterol (LDL-C) levels recommended …

Introduction Low-density lipoprotein cholesterol (LDL-C) is among the most important
modifiable risk factors for cardiovascular disease. In very high-risk patients, the European …

Introduction This study characterizes patients receiving evolocumab in clinical practice and
assesses treatment effectiveness, safety and persistence outcomes across five countries …